Guizhou Braun develops diabetes secret recipe

Today, Guizhou Brilliance, which has been the leader of the Miao medicine, issued an announcement. On April 15th, the company signed the “Miao Medicine Cooperative Development Agreement” with Yang Guoshun and Yang Ailong. After negotiation, the two parties will jointly develop the ancestral therapy of Yang Guoshun and Yang Ailong for the treatment of diabetes miao medicine prescriptions. . The company stated that it is possible to buy off the rights of Yang Guoshun and Yang Ailong at any time and the buyout amount will not exceed 100 million yuan.

Guizhou Braun announced today that, given that Yang Guoshun and Yang Ailong have ancestral treatment of diabetes mellitus medicine secret recipe (hereinafter referred to as recipe), after Yang Guoshun and Yang Ailong's multi-year medical practice, the recipe can better control blood sugar, and some patients still maintain stable blood sugar after drug withdrawal. . Guizhou Braun visited some patients with medication and confirmed that the secret formula has obvious therapeutic effects on diabetes.

The two parties reached an agreement that Yang Guoshun and Yang Ailong volunteered to cooperate with the Guizhou Braun. Guizhou Braun will carry out pre-clinical pharmacodynamics, toxicology, pharmacy, and other research projects with well-known experts and institutions within the United Nations, and report to the state administration based on the results of the study. The department approves registration of new drugs. In the pre-clinical studies, Guizhou Braun can invest or jointly set up a nationwide diabetes specialist hospital or specialist outpatient clinic to produce and sell the secret prescription medicine.

"Daily Economic News" reporter found from the agreement that Guizhou Braun paid for 5 million yuan to Yang Guoshun and Yang Ailong five days after the agreement was signed. After the secret prescription has been approved by the relevant national authorities as a new drug and marketed, or after setting up specialty hospitals or specialty clinics to make profits (net of investment costs), Guizhou Braun will obtain 90% of profits, while Yang Guoshun and Yang Ailong will share another 10%. If the secret recipe has not been approved as a new drug by the relevant national authorities, the loss of research and development expenses will be borne by Guizhou Braun.

For the development of this area, Orient Securities clearly pointed out in its report. With the rising standard of living of the people, the incidence of diabetes is also rising year by year. With the advent of the aging population in China, the number of people with diabetes will continue to grow. The market size of the overall diabetes medication in China in 2012 is about 27 billion yuan. If R&D is successful, it will bring new profit growth points for Guizhou Braun.

Guizhou Braun also stated that due to the complexity, risk, and uncertainty of the development of new drugs, the secret cooperation in developing the project has a long period and large investment, and the research in each phase is risky.